TCBP News and Press, TC BioPharm (Holdings) plc

TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient PR Newswire First patient in Cohort B achieved CR after 2 nd dose of TCB008 EDINBURGH, Scotland , June 11, 2025 /PRNewswire/ -- TC BioPharm (Holdings) P...

2025-03-21 12:29:45 ET TC BioPharm (NASDAQ: TCBP) , a clinical-stage biotech company focused on allogeneic gamma-delta T cell therapies, announced it will be delisted from the Nasdaq Stock Market following a determination by the Nasdaq Hearings Panel. The decision, dated March 20, 2025,...

TCBP Announces Transition from Nasdaq to OTC Markets PR Newswire EDINBURGH, Scotland , March 21, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company"), (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic...

2025-03-18 09:35:00 ET TC BioPharm (NASDAQ: TCBP) , a clinical-stage biotechnology company developing allogeneic gamma-delta T cell therapies, is implementing a strategic shift to a decentralized model, outsourcing key functions to contract development and manufacturing organizations (C...

TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead PR Newswire The company is expected to reduce core operational burn by 55% when compared to 2024 EDINBURGH, Scotland , March 18, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC B...

2025-03-08 14:36:00 ET More on markets Wall Street Lunch: Bye-Bye Bro Bubble Market And Economic Insights From February 2025 SPY: Hold On Tight, Things Are Getting Worse Elon Musk suggests U.S. should privatize Postal Service and Amtrak BTIG’s ...

2025-03-05 10:01:51 ET TC BioPharm (NASDAQ: TCBP) a clinical-stage biotechnology company developing allogeneic gamma-delta T cell therapies, announced the execution of a non-binding letter of intent to acquire a commercial-stage ophthalmic pharmaceutical company specializing in glaucoma...

2025-03-05 08:49:03 ET More on TC Biopharm TC BioPharm to implement ADS ratio change Seeking Alpha’s Quant Rating on TC Biopharm Historical earnings data for TC Biopharm Financial information for TC Biopharm Read the full article on Seeking A...

TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company PR Newswire FDA-approved product in a multi-billion-dollar market Revenue generation projected in 2025 EDINBURGH, Scotland , March 5, 2025 /PRNew...

2025-02-20 10:05:00 ET TC BioPharm (NASDAQ: TCBP) announced that CEO Bryan Kobel will participate in the Cancer Progress Panel at the 18th Annual European Life Sciences CEO Forum on Feb. 27 at 1:10 p.m. CET in Zurich. The forum, set for Feb. 26-27 at the Hilton Zurich Airport Hotel, wil...